30 March - 5 April 2019
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Mavenclad (cladribine) approved in USA
Mavenclad (cladribine) has been approved by the FDA, the US drug regulator, for relapsing forms of MS, including relapsing remitting MS and “active” secondary progressive MS. In the UK, Mavenclad has been approved as an NHS treatment since 2017.
MS Trust link: Mavenclad
Gabapentin and pregabalin reclassified
From April 1, gabapentin and pregabalin have been reclassified as controlled drugs. This has resulted in changes to how they are prescribed, particularly for repeat prescriptions.
MS Trust link: Gabapentin and pregabalin - new rules for prescriptions
MS Trust launches 'Move it For MS' exercise campaign for MS Awareness Week
25 April 2019
This MS Awareness Week, we are calling on people with MS to pop on their pumps and introduce a little activity into their daily routine. Staying active doesn’t need to mean running marathons or going to the gym, it’s about doing it at your own level, at your own pace. Doing it YOUR way.
Don’t judge a book by its cover – Becky’s books help the MS Trust
24 April 2019
Our supporter Becky is raising money for the MS Trust with the sale of her beautiful handmade notebooks.
EMA recommends temporary restriction on use of Lemtrada
12 April 2019
The European Medicines Agency has recommended a temporary restriction on people who should start treatment with Lemtrada while a review of side effects is carried out.